Vaccines against tuberculosis: A review

Bhargava, Salil; Choubey, Satyadeo

doi:10.1016/j.ijtb.2016.02.005

Cited by 11 publications

(6 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…186,187 Further, Mtb72F has also been shown to stimulate T cell proliferation and IFN-g secretion in PPD positive healthy individuals. 187,188 Currently, the safety and immunogenicity of Mtb72F vaccine have been evaluated in some Phase II clinical studies performed in healthy PPD-positive adults in the Philippines, 189 in healthy HIV-negative adolescents in South Africa, 190 and in adults in Taiwan and Estonia. 191 All three Phase II clinical trials showed similar safety profiles and antibody responses, and indicated that this vaccine could induce strong CD4 C T cell immune responses, rather than CD8 C T cell responses.…”

Section: Mtb72fmentioning

confidence: 99%

“…These clinical trials yielded similar results, in that H4:IC31 had an acceptable safety profile in human beings and induced IFN-g production and a multifunctional CD4 C Th1 response. 188,197 Additionally, a Phase II clinical trial has been completed by Aeras in healthy adolescents in South Africa (ClinicalTrials.gov Identifier: NCT02075203). The results demonstrated that this vaccine was safe and immunogenic, and indicated that a 15 mg dose induced the optimal immune response.…”

Section: Mtb72fmentioning

confidence: 99%

See 1 more Smart Citation

The current status, challenges, and future developments of new tuberculosis vaccines

Gong

Liang

2018

Human Vaccines & Immunotherapeutics

103

View full text Add to dashboard Cite

Mycobacterium tuberculosis complex causes tuberculosis (TB), one of the top 10 causes of death worldwide. TB results in more fatalities than multi-drug resistant (MDR) HIV strain related coinfection. Vaccines play a key role in the prevention and control of infectious diseases. Unfortunately, the only licensed preventive vaccine against TB, bacilli Calmette-Guérin (BCG), is ineffective for prevention of pulmonary TB in adults. Therefore, it is very important to develop novel vaccines for TB prevention and control. This literature review provides an overview of the innate and adaptive immune response during M. tuberculosis infection, and presents current developments and challenges to novel TB vaccines. A comprehensive understanding of vaccines in preclinical and clinical studies provides extensive insight for the development of safer and more efficient vaccines, and may inspire new ideas for TB prevention and treatment.

show abstract

Section: Mtb72fmentioning

confidence: 99%

Section: Mtb72fmentioning

confidence: 99%

The current status, challenges, and future developments of new tuberculosis vaccines

Gong

Liang

2018

Human Vaccines & Immunotherapeutics

103

View full text Add to dashboard Cite

show abstract

“…Several phase I clinical trials evaluating the safety and immunogenicity of H4:IC31 have been conducted in TB-negative, HIV-negative, BCG-unvaccinated adults in Switzerland (NCT02420444), in TB-negative, HIV-negative, BCG-vaccinated adults in South Africa (NCT02109874), in HIV-negative, BCG-vaccinated adults in Sweden (NCT02066428) and Finland (NCT02074956), and in HIV-uninfected, HIV-unexposed, BCG-primed infants in South Africa (NCT01861730). These clinical trials have produced similar results, demonstrating that H4:IC31 is safe in humans and induces IFN-γ production and multifunctional CD4 + Th1 responses [ 87 , 150 , 151 ]. In 2020, a phase 1b randomized clinical trial (NCT02378207) was conducted in Cape Town, South Africa.…”

Section: The Clinical Pipeline Of Tb Vaccinesmentioning

confidence: 85%

Next-Generation TB Vaccines: Progress, Challenges, and Prospects

Zhuang,

Ye,

et al. 2023

Vaccines

View full text Add to dashboard Cite

Tuberculosis (TB), caused by Mycobacterium tuberculosis (MTB), is a prevalent global infectious disease and a leading cause of mortality worldwide. Currently, the only available vaccine for TB prevention is Bacillus Calmette–Guérin (BCG). However, BCG demonstrates limited efficacy, particularly in adults. Efforts to develop effective TB vaccines have been ongoing for nearly a century. In this review, we have examined the current obstacles in TB vaccine research and emphasized the significance of understanding the interaction mechanism between MTB and hosts in order to provide new avenues for research and establish a solid foundation for the development of novel vaccines. We have also assessed various TB vaccine candidates, including inactivated vaccines, attenuated live vaccines, subunit vaccines, viral vector vaccines, DNA vaccines, and the emerging mRNA vaccines as well as virus-like particle (VLP)-based vaccines, which are currently in preclinical stages or clinical trials. Furthermore, we have discussed the challenges and opportunities associated with developing different types of TB vaccines and outlined future directions for TB vaccine research, aiming to expedite the development of effective vaccines. This comprehensive review offers a summary of the progress made in the field of novel TB vaccines.

show abstract

“…Therapeutic vaccines shed light on TB control by inducing antigen specific immune responses against Mtb in vivo (8), and Mtb potent antigen encoding genes are delivered into host cells via plasmid, adenovirus or lentivirus for in vivo gene expression (9,10). As a novel immunotherapy strategy, therapeutic vaccine has been successful for TB control not only in latent TB infection model but also in acute infection model (11,12).…”

Section: Tuberculosis (Tb) a Worldwide Infectious Disease Caused Bymentioning

confidence: 99%

Assessment of recombinant plasmid expressing fusion antigen Ag85B-Rv3425 in management of acute tuberculosis infection in mice

et al. 2018

View full text Add to dashboard Cite

Abstract. The emergence of drug-resistant tuberculosis (TB) and HIV-TB co-infection fuels an urgent need to develop novel therapeutic approaches, including therapeutic vaccines. Therapeutic vaccines have been proven to be a good strategy by inducing antigen specific immune responses against TB infection. In the present study, a recombinant plasmid based on lentiviral vector expressing fusion antigen Ag85B-Rv3425 (A3), and was constructed the immunogenicity and treatment effects in TB mice were assessed. The results showed that A3 delivered by the plasmid could be expressed appropriately in vivo and induced higher production of tumor necrosis factor-α and interleukin-2 compared with A3 recombinant protein in mice. Moreover, the recombinant plasmid expressing A3 confered resistance to acute TB infection in mice, characterized by a reduction in the bacterial load in the lungs and spleen, as well as attenuated TB lesions in lung tissues. These results implicated that the recombinant plasmid based on lentiviral vector expressing A3 is a potent and promising therapeutic agent to treat acute TB infection.

show abstract

Vaccines against tuberculosis: A review

Cited by 11 publications

References 31 publications

The current status, challenges, and future developments of new tuberculosis vaccines

The current status, challenges, and future developments of new tuberculosis vaccines

Next-Generation TB Vaccines: Progress, Challenges, and Prospects

Assessment of recombinant plasmid expressing fusion antigen Ag85B-Rv3425 in management of acute tuberculosis infection in mice

Contact Info

Product

Resources

About